Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Breast01 izalontamab brengitecan vs treatment of physician's choice in first-line metastatic TNBC or ER-low, HER2-negative breast cancer ineligible for PD-1/PD-L1 therapy
jRCT2041250102Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in triple-negative breast cancer (TNBC) and breast cancer (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival by RECIST v1.1 per BICR. Started Oct 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2041250102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250102.